TransEnterix has acquired the assets of MST Medical Surgery Technologies (MST) in a cash and stock transaction.
The acquisition will add the target company’s advanced surgical image analytics technology capabilities to TransEnterix’s Senhance digital laparoscopy platform.
The transaction will be completed in two separate cash and stock tranches, with $5.8m being paid in cash and 3.15 million in shares in the first tranche. The second tranche will include $6.6m payable in either cash or stock.
MST’s R&D team will be transferred to an Israel-based subsidiary of TransEnterix and operate under the name TransEnterix Israel.
TransEnterix is an American medical device company, while MST is an Israel-based developer of image analysis software.
The acquisition is part of TransEnterix’s strategy of digitising the interface between the surgeon and the patient.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
MeMed has raised $70m to support the development of diagnostics products.
The funding was provided by new and existing investors, including Foxconn, Caesarea Medical, Clal Insurance, Phoenix Insurance, Social Capital, WTI, OurCrowd and Horizons Ventures.
The funds will be utilised to promote MeMed BV, an immune-based test for differentiating bacterial and viral infections, as well as the MeMed Key point-of-care platform.
The financing will also be used towards the expansion of MeMed’s pipeline of tests that integrate machine learning and immune-based measurements to handle clinical challenges.
Based in Israel, MeMed is a medical technology company that develops diagnostic solutions.
ViaCyte has secured a $10m investment from W. L. Gore & Associates (Gore) in the form of a convertible promissory note.
The new investment follows an investment made in March 2017 for the development of cell encapsulation technologies by combining Gore’s material science technology with ViaCyte’s expertise in human cell replacement therapies.
The two companies focused their efforts on the PEC-Encap™ product targeted as a cure for patients with type 1 diabetes.
ViaCyte is a regenerative medicine company focussed on the development of implantable medical therapies, while Gore is a materials science company. Both are based in the US.